Send to:

Choose Destination
See comment in PubMed Commons below
Ann Vasc Dis. 2009;2(3):148-58. doi: 10.3400/avd.AVDoa090017. Epub 2010 Mar 29.

A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1).

Author information

  • 1Department of Clinical Epidemiology and Systems, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.



For new evidence of treatment with statins in Japanese hypercholesterolemic patients, we performed an open-label, randomized, parallel-group comparative study to assess the effect of rosuvastatin 2.5 mg and pravastatin 10 mg on plasma lipids.


A total of 100 patients in whom the target control levels of LDL-cholesterol (LDL-C) set by the Japan Atherosclerosis Society Guidelines (JASGL2007) had not been achieved were randomly assigned to receive rosuvastatin 2.5 mg / day or pravastatin 10 mg / day for 8 weeks. The primary endpoint was the percent change of LDL-C at week 8.


LDL-C was lowered by -40.3% (from 160.3 to 95.1 mg / dL) in the rosuvastatin group and -22.9% (from 162.9 to 126.0 mg / dL) in the pravastatin group, at week 8 (P < 0.001 vs. pravastatin). LDL-C / HDL-C ratio was lowered by -41.3% (from 2.85 to 1.69) and -20.6% (from 2.81 to 2.24), respectively (P < 0.001 vs. pravastatin). The rate of achievement of the target LDL-C control level at week 8 was significantly higher in the rosuvastatin group (98.0%) than in the pravastain group (78.7%) (P = 0.003). Both drugs were well tolerated.


Rosuvastatin 2.5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than pravastatin 10 mg, and its safety profile is similar to pravastatin 10 mg.


LDL-C; LDL-C / HDL-C ratio; Statin; guideline

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk